Loading...

SCYX SCYNEXIS INC Operational Disruptions 8-K Filing

SCYN

SCYX

SCYNEXIS INC

(SCYX)

2023 8-K

Stock Split Announcement

Stock Split Approval

Director's Retirement

Conference Call Update

Private Placement Announcement

Asset Acquisition

License Agreement Update

Voluntary Delisting

Stock Offering Agreement

Investor Update

Annual Meeting of Stockholders

Quantitative Data

Regulation FD Disclosure

Amendment to License Agreem...

Recall and Clinical Hold

Recall and Clinical Study Hold

Termination of Loan Agreeme...

Annual Meeting of Stockholders

Quantitative Data

External Links:

SCYNEXIS is recalling BREXAFEMME and placing a hold on clinical studies of ibrexafungerp due to a risk of cross contamination with a non-antibacterial beta-lactam drug substance.

AI Assistant

SCYNEXIS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.